Fact-checked by Dr. J. Adam, MD on . See our fact-checking policy.
Consumer behavioral-app brand layered with GLP-1 prescribing — strong app, less clinical depth
Confirm current monthly cost, dose-based increases, shipping, labs, and cancellation terms before enrollment.
Verify who reviews the intake, how follow-ups work, and what support is available for side effects.
For compounded medications, verify pharmacy type, formulation, state eligibility, and quality disclosures.
Compounded GLP-1 medications are not FDA-approved. Eligibility, pricing, pharmacy, and medication availability may change and require clinician review.
Noom Med is the medication-prescribing arm of Noom, the largest behavioral-weight-loss app brand in the U.S. The app's psychology-based curriculum and habit-tracking infrastructure are mature and the brand has a substantial existing user base. For Noom users who want to add GLP-1 prescribing into the same app relationship, Noom Med is a reasonable continuation.
Noom Med is layered on top of Noom's existing app subscription, and the GLP-1 prescribing is the secondary product, not the primary one. Clinical depth is shallow versus specialist-led platforms like Form Health. Onboarding is slow (5–10 business days). For patients who don't already use Noom, the app overhead provides limited additional value vs picking a more focused GLP-1 platform.
Noom Med makes sense for committed existing Noom users. As a primary GLP-1 choice, Form, NexLife, and Ro all rank higher.
Noom Med pricing ranges from $70/mo app + medication. Starting price is $70/month. Pricing details and any titration upcharges are described above in the pricing section.
Noom Med is an established telehealth program. Strong app, weaker as a pure GLP-1 program. Always verify a provider's pharmacy partnerships, prescribing physician credentials, and state availability before signing up.
Most direct-to-consumer compounded GLP-1 programs do not accept insurance for the medication itself. If insurance coverage matters to you, see our insurance pathway providers (Mochi Health, Ro, Form Health) and our insurance hub.
Noom Med prescribes: Compounded semaglutide, Wegovy, Zepbound.
Noom Med is available in Most US states.
Eligibility is determined by an intake questionnaire and clinical review. Generally, FDA-approved weight-loss criteria are BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (Type 2 diabetes, hypertension, dyslipidemia, sleep apnea). Off-label compounded prescribing is at the discretion of the prescribing clinician.
Editorial note. By GLP Agonists Editorial · Last updated June 12, 2026. This review is editorially independent. See our methodology and editorial disclosure. Not medical advice — always consult a licensed clinician.